CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of risankizumab in patients with moderate to severe crohn’s disease: Results from the one-year SEQUENCE open-label Long-term extension
DOI 10.1055/s-0045-1810726
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Peyrin-Biroulet, R Atreya, S Danese, J O Lindsay, J C Chapman, T Anschutz, X Huang, J Zambrano, A Platt, N Joshi, R K Cross
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2025
Jahrgang / SeitenJg. 63 · S. e418-e419
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of risankizumab in patients with moderate to severe crohn’s disease: Results from the one-year SEQUENCE open-label Long-term extension
Zitieren
Zitierempfehlung
L Peyrin-Biroulet, R Atreya, S Danese, J O Lindsay, J C Chapman, T Anschutz, X Huang, J Zambrano, A Platt, N Joshi, R K Cross (2025) Efficacy and safety of risankizumab in patients with moderate to severe crohn’s disease: Results from the one-year SEQUENCE open-label Long-term extension. Zeitschrift für Gastroenterologie, 63 (08), e418-e419. https://doi.org/10.1055/s-0045-1810726
Mit CareLit weiterarbeiten